Publication | Open Access
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
63
Citations
32
References
2023
Year
Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.
| Year | Citations | |
|---|---|---|
Page 1
Page 1